Cargando…

Peptide vaccine as an adjuvant therapy for glypican‐3‐positive hepatocellular carcinoma induces peptide‐specific CTLs and improves long prognosis

There is no established postoperative adjuvant therapy for hepatocellular carcinoma (HCC), and improvement of patient prognosis has been limited. We conducted long‐term monitoring of patients within a phase II trial that targeted a cancer antigen, glypican‐3 (GPC3), specifically expressed in HCC. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taniguchi, Masatake, Mizuno, Shoichi, Yoshikawa, Toshiaki, Fujinami, Norihiro, Sugimoto, Motokazu, Kobayashi, Shin, Takahashi, Shinichiro, Konishi, Masaru, Gotohda, Naoto, Nakatsura, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419030/ https://www.ncbi.nlm.nih.gov/pubmed/32449239 http://dx.doi.org/10.1111/cas.14497

Ejemplares similares

Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017)

Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery
por: Miura, Masahiro, et al.
Publicado: (2020)

Plasma and tumoral glypican‐3 levels are correlated in patients with hepatitis C virus‐related hepatocellular carcinoma
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

A glypican-3-derived peptide vaccine against hepatocellular carcinoma
por: Sawada, Yu, et al.
Publicado: (2012)

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017)

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
por: Sawada, Yu, et al.
Publicado: (2016)

Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: An autopsy case
por: Sawada, Yu, et al.
Publicado: (2013)

Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2016)

Component with abundant immune‐related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis
por: Yagi, Naoki, et al.
Publicado: (2022)

Pancreas‐preserving resection of lower biliary tract adenocarcinoma: A coring‐out technique
por: Nishida, Yasunori, et al.
Publicado: (2017)

Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification
por: Takahashi, Daigoro, et al.
Publicado: (2018)

Identification of an H2-K(b) or H2-D(b) restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide
por: IWAMA, TATSUAKI, et al.
Publicado: (2013)

Next-Generation Cancer Immunotherapy Targeting Glypican-3
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

Early postoperative decrease of skeletal muscle mass predicts recurrence and poor survival after surgical resection for perihilar cholangiocarcinoma
por: Yasuta, Sho, et al.
Publicado: (2022)

Cancer immunotherapy‐targeted glypican‐3 or neoantigens
por: Shimizu, Yasuhiro, et al.
Publicado: (2018)

Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
por: TADA, YOSHITAKA, et al.
Publicado: ( 201)

Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model
por: Fujinami, Norihiro, et al.
Publicado: (2016)

Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances
por: Charneau, Jimmy, et al.
Publicado: (2021)

BRAF V600E potentially determines “Oncological Resectability” for “Technically Resectable” colorectal liver metastases
por: Kobayashi, Shin, et al.
Publicado: (2021)

Evaluation of liver function using gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging based on a three-dimensional volumetric analysis system
por: Kudo, Masashi, et al.
Publicado: (2018)

Liver functional assessment using time-associated change in the liver-to-spleen signal intensity ratio on enhanced magnetic resonance imaging: a retrospective study
por: Kudo, Masashi, et al.
Publicado: (2023)

Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: Two case reports
por: Suzuki, Shiro, et al.
Publicado: (2014)

Peptide vaccines for hepatocellular carcinoma
por: Nobuoka, Daisuke, et al.
Publicado: (2013)

Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma
por: Suzuki, Shiro, et al.
Publicado: (2016)

Identification of glypican-3-derived long peptides activating both CD8(+) and CD4(+) T cells; prolonged overall survival in cancer patients with Th cell response
por: Sayem, Mohammad A., et al.
Publicado: (2015)

Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes
por: SAWADA, YU, et al.
Publicado: (2014)

Histological tumor necrosis in pancreatic cancer after neoadjuvant therapy
por: Kudo, Masashi, et al.
Publicado: (2022)

Extracellular miRNAs as Predictive Biomarkers for Glypican-3-Derived Peptide Vaccine Therapy Response in Ovarian Clear Cell Carcinoma
por: Ukai, Mayu, et al.
Publicado: (2021)

Peptide intra-tumor injection for cancer immunotherapy: Enhancement of tumor cell antigenicity is a novel and attractive strategy
por: Nobuoka, Daisuke, et al.
Publicado: (2013)

Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery
por: Akazawa, Yu, et al.
Publicado: (2019)

Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3
por: Kawashima, Issei, et al.
Publicado: (2015)

CTL-Derived Exosomes Enhance the Activation of CTLs Stimulated by Low-Affinity Peptides
por: Wu, Shu-Wei, et al.
Publicado: (2019)

Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy
por: YOSHIKAWA, TOSHIAKI, et al.
Publicado: (2014)

Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate
por: SUGAI, SHIORI, et al.
Publicado: (2016)

A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer
por: OFUJI, KAZUYA, et al.
Publicado: (2014)

Complement as an Endogenous Adjuvant for Dendritic Cell-Mediated Induction of Retrovirus-Specific CTLs
por: Bánki, Zoltán, et al.
Publicado: (2010)

Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients
por: Suefuji, Y, et al.
Publicado: (2001)

Hypothyroidism and hypopituitarism as immune-related adverse events due to lenvatinib plus pembrolizumab therapy in the immediate postoperative period after laparoscopic hepatectomy for liver metastases from gastric cancer: a case report
por: Sasaki, Kimimasa, et al.
Publicado: (2021)

Higher human lymphocyte antigen class I expression in early‐stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes
por: Akazawa, Yu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_03tkkvcead2plst99kppilhjkp